Aura Biosciences Inc (AURA)

Currency in USD
6.84
+0.21(+3.17%)
Closed·
After Hours
6.840.00(0.00%)
·
AURA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
AURA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.486.89
52 wk Range
4.3512.38
Key Statistics
Prev. Close
6.84
Open
6.58
Day's Range
6.48-6.89
52 wk Range
4.35-12.38
Volume
140.01K
Average Volume (3m)
215.97K
1-Year Change
-22.2%
Book Value / Share
2.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AURA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.50
Upside
+214.33%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Aura Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Aura Biosciences Inc Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Aura Biosciences Inc SWOT Analysis


Bel-sar's Promise
Explore bel-sar's potential in treating choroidal melanoma and bladder cancer, with 80% of patients maintaining tumor control in Phase 2 trials
Clinical Progress
Delve into Aura's ongoing Phase 3 CoMpass trial for choroidal melanoma and planned Phase 2 trials for choroidal metastasis and ocular surface cancers
Market Opportunities
Discover Aura's estimated addressable market of 8,000 early-stage choroidal melanoma patients annually in the U.S. and EU, with potential peak sales of $1.5 billion
Financial Outlook
Learn about Aura's strong financial position with $187 million in cash, providing runway into 2026, and a $23 price target from JMP Securities
Read full SWOT analysis

Compare AURA to Peers and Sector

Metrics to compare
AURA
Peers
Sector
Relationship
P/E Ratio
−4.5x−3.6x−0.5x
PEG Ratio
1.550.010.00
Price/Book
3.3x2.8x2.6x
Price / LTM Sales
-10.0x3.3x
Upside (Analyst Target)
231.8%183.7%43.5%
Fair Value Upside
Unlock0.5%6.9%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.50
(+214.33% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.55 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AURA Income Statement

People Also Watch

263.10
AVAV
-0.62%
3.520
IMRX
-1.40%
2.910
ABSI
-1.36%
3.60
ALT
-1.91%
264.32
BIO
-2.89%

FAQ

What Stock Exchange Does Aura Biosciences Trade On?

Aura Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aura Biosciences?

The stock symbol for Aura Biosciences is "AURA."

What Is the Aura Biosciences Market Cap?

As of today, Aura Biosciences market cap is 424.11M.

What Is Aura Biosciences's Earnings Per Share (TTM)?

The Aura Biosciences EPS (TTM) is -1.90.

When Is the Next Aura Biosciences Earnings Date?

Aura Biosciences will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is AURA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Aura Biosciences Stock Split?

Aura Biosciences has split 0 times.

How Many Employees Does Aura Biosciences Have?

Aura Biosciences has 108 employees.

What is the current trading status of Aura Biosciences (AURA)?

As of 07 Aug 2025, Aura Biosciences (AURA) is trading at a price of 6.84, with a previous close of 6.84. The stock has fluctuated within a day range of 6.48 to 6.89, while its 52-week range spans from 4.35 to 12.38.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.